1832 Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

1832 Asset Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-9	Closed	-$3.11K	–	896
2024 Q1	$3.11K	Buy	+9	New	+$2.96K	﹤0.01%	830
2023 Q2	–	Sell	-11,204	Closed	-$5.37M	–	853
2023 Q1	$5.37M	Buy	+11,204	New	+$5.24M	0.01%	400
2022 Q2	–	Sell	-3,081	Closed	-$1.71M	–	866
2022 Q1	$1.71M	Buy	+3,081	New	+$1.86M	﹤0.01%	571
2016 Q4	–	Sell	-7,500	Closed	-$1.23M	–	687
2016 Q3	$1.23M	Hold	7,500	–	–	﹤0.01%	440
2016 Q2	$1.08M	Buy	7,500 +3,500	+88%	+$499K	﹤0.01%	407
2016 Q1	$919K	Buy	+4,000	New	+$525K	﹤0.01%	415

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

1832 Asset Management's BIO Position: Q2 2024 in Review

1832 Asset Management sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2024, closing a stake of 9 shares — an estimated $3.11K sold.

1832 Asset Management first reported a position in BIO in Q1 2016 and held it in 6 quarters. The position peaked at $5.37M in Q1 2023. 440 funds tracked by Wall St. Rank hold BIO as of Q2 2024.

1832 Asset Management reported no remaining Bio-Rad Laboratories Class A position as of Q2 2024 after selling out during the quarter.
1832 Asset Management sold 9 Bio-Rad Laboratories Class A shares in Q2 2024, an estimated $3.11K.
1832 Asset Management first reported a position in Bio-Rad Laboratories Class A in Q1 2016 and held it in 6 quarters.
1832 Asset Management's Bio-Rad Laboratories Class A position peaked at $5.37M in Q1 2023.
440 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2024.

Based on 1832 Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.